Aurobindo is offering a new generic, and the company also has received approval from the Food and Drug Administration for another generic.
Aurobindo is launching eefavirenz/emtricitabine/tenofovir disoproxil fumarate tablets, in a dosage strength of 600mg/200mg/300mg.
The medication is the generic of Gilead’s Atripla.
It is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.
Efavirenz/emtricitabine/tenofovir disoproxil fumarate tablets has a market value of roughly $482 million, for the 12 months ending January 2021, according to IQVIA.